The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2023 | Results from AGILE: ivosidenib-azacitidine vs azacitidine-placebo in patients with IDH1m AML
Vidhya Murthy, MBBS, MRCP, FRCPath, FRCP, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, discusses results from the Phase III AGILE trial (NCT03173248), which investigated the safety and efficacy of ivosidenib-azacitidine versus azacitidine-placebo in older patients with IDH1-mutated acute myeloid leukemia (AML) unfit for intensive chemotherapy. Results demonstrated that patients in the ivosidenib-azacitidine arm demonstrated a superior event-free survival (EFS) and overall survival (OS), as well as an improved neutrophil count. Dr Murthy also discusses quality of life (QoL) data obtained in this trial and the toxicity profile of this combination. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
